Blood-soluble Fas Levels are Increased in Type 2 Diabetic Patients with Peripheral Vascular Disease

García‐Unzueta, María Teresa; Pesquera, C.; Calzada, Elizabeth; Mora, A.; Muñoz, Prior; Llorca, Javier; Morchón, N.; Fernández-González, María Dolores; Amado, J A

doi:10.1055/s-2006-954585

Cited by 4 publications

(4 citation statements)

References 21 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This implies that the real impact of Lp(a) on diabetic foot ulcerations has to be further investigated by prospective studies and/or by the assessment of apo(a) polymorphism that can be modified by environmental conditions [1]. However, many nontraditional risk factors other than Lp(a) and Hcy can have a role in the development of diabetic foot ulcerations [20,43]. So it may be of clinical interest the identification of a panel of risk factors to stratify the individual risk of each diabetic patient of developing foot ulcerations.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus

Gazzaruso

Coppola²,

Montalcini

et al. 2011

Endocrine

View full text Add to dashboard Cite

Neuropathy and peripheral artery disease represent the main pathophysiological conditions underlying diabetic foot. Several studies showed that Lipoprotein(a)-Lp(a)-and homocysteine (Hcy) can be associated with diabetic complications, but their relationship with diabetic foot is unclear. Aim of this study was to investigate whether Lp(a) and Hcy were associated with diabetic foot ulcerations, classified according to the presence of peripheral artery disease (PAD) or neuropathy. From among consecutive type 2 diabetic attending at the Diabetic Foot Clinic 27 subjects with vascular diabetic foot (VDF), 43 with neuropathic diabetic foot (NDF) and 52 controls without foot ulceration, neuropathy, and PAD were enrolled. Both Lp(a) (26.1 ± 22.7 vs. 14.9 ± 19.5 mg/dl; P = 0.003) and Hcy levels (15.4 ± 5.7 vs. 12.2 ± 5.1 μmol/l; P = 0.022) were significantly greater in the VDF group than in controls. Lp(a) levels were significantly lower in the NDF group than in controls (6.9 ± 8.1 versus 14.9 ± 19.5 mg/dl; P = 0.009), while no difference in Hcy levels was found. Multiple logistic regression analysis showed that Hcy was associated with VDF (OR: 1.11; 95% CI: 1.07-14.1; P = 0.048). Lp(a) did not enter the model, but its P-value was very near to the significant level (OR: 1.09; 95% CI: 0.99-12.05; P = 0.059). Moreover, low Lp(a) levels were associated with NDF (OR: 0.84; 95% CI: 0.21-0.96; P = 0.039). Our study has shown for the first time that high Lp(a) and Hcy levels are associated with the development of VDF, while low Lp(a) levels appear to be associated with delayed wound healing in patients with neuropathic foot ulcerations.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Some studies showed an association of both Lp(a) and Hcy levels with PAD [12,19], but others did not [20]. A relationship between Lp(a) and diabetic neuropathy was not observed by specific studies [9,21], while conflicting results are available in the literature on the association between Hcy and neuropathy [15,19,22].…”

Section: Introductionmentioning

confidence: 99%

Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus

Gazzaruso

Coppola²,

Montalcini

et al. 2011

Endocrine

View full text Add to dashboard Cite

show abstract

“…Impairment of the Fas/FasL system in subjects with increased cardiovascular risk is reported to include increased serum sFas and decreased sFasL [7]. In subjects with type 2 DM, increased sFas levels are associated with peripheral vascular disease [8]. In dialysis patients, serum sFas is increased in subjects with atherosclerosis [9,10] while sFasL is not altered [10].…”

Section: Introductionmentioning

confidence: 99%

Serum levels of sFas and sFasL in subjects with type 2 diabetes — the impact of arterial hypertension

Stoynev¹,

Kalinov

Кirilov

et al. 2014

Open Medicine

View full text Add to dashboard Cite

show abstract

“…This makes the usefulness of the different diagnostic criteria for MetS, questionable. Therefore, many studies are trying to identify novel biomarkers that predict the risk for vascular diseases [6,7] . It is suggested that leptin infl uences infl ammation and coagulation through its effects on factors involved on platelet aggregability, thrombogenesis, and fi brinolysis.…”

Section: Introductionmentioning

confidence: 99%

Effects of Leptin Replacement on Risk Factors for Cardiovascular Disease in Genetically Leptin-deficient Subjects

Paz-Filho¹,

Andrews²,

Esposito

et al. 2008

Horm Metab Res

View full text Add to dashboard Cite

Blood-soluble Fas Levels are Increased in Type 2 Diabetic Patients with Peripheral Vascular Disease

Abstract: Plasma sFas may be an independent marker of PVD in type 2 diabetes mellitus patients.

Cited by 4 publications

References 21 publications

Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus

Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus

Serum levels of sFas and sFasL in subjects with type 2 diabetes — the impact of arterial hypertension

Effects of Leptin Replacement on Risk Factors for Cardiovascular Disease in Genetically Leptin-deficient Subjects

Contact Info

Product

Resources

About